1. Home
  2. ZBAI vs MYNZ Comparison

ZBAI vs MYNZ Comparison

Compare ZBAI & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZBAI
  • MYNZ
  • Stock Information
  • Founded
  • ZBAI 2015
  • MYNZ 2021
  • Country
  • ZBAI United States
  • MYNZ Germany
  • Employees
  • ZBAI N/A
  • MYNZ N/A
  • Industry
  • ZBAI Professional Services
  • MYNZ Biotechnology: Pharmaceutical Preparations
  • Sector
  • ZBAI Consumer Discretionary
  • MYNZ Health Care
  • Exchange
  • ZBAI Nasdaq
  • MYNZ Nasdaq
  • Market Cap
  • ZBAI 6.4M
  • MYNZ 7.6M
  • IPO Year
  • ZBAI N/A
  • MYNZ 2021
  • Fundamental
  • Price
  • ZBAI $0.38
  • MYNZ $1.96
  • Analyst Decision
  • ZBAI
  • MYNZ Buy
  • Analyst Count
  • ZBAI 0
  • MYNZ 2
  • Target Price
  • ZBAI N/A
  • MYNZ $14.00
  • AVG Volume (30 Days)
  • ZBAI 8.3M
  • MYNZ 185.8K
  • Earning Date
  • ZBAI 06-06-2025
  • MYNZ 08-05-2025
  • Dividend Yield
  • ZBAI N/A
  • MYNZ N/A
  • EPS Growth
  • ZBAI N/A
  • MYNZ N/A
  • EPS
  • ZBAI N/A
  • MYNZ N/A
  • Revenue
  • ZBAI $720,000.00
  • MYNZ $893,991.00
  • Revenue This Year
  • ZBAI N/A
  • MYNZ $26.06
  • Revenue Next Year
  • ZBAI N/A
  • MYNZ $4.97
  • P/E Ratio
  • ZBAI N/A
  • MYNZ N/A
  • Revenue Growth
  • ZBAI 44.00
  • MYNZ N/A
  • 52 Week Low
  • ZBAI $0.27
  • MYNZ $1.34
  • 52 Week High
  • ZBAI $2.50
  • MYNZ $19.00
  • Technical
  • Relative Strength Index (RSI)
  • ZBAI N/A
  • MYNZ 53.58
  • Support Level
  • ZBAI N/A
  • MYNZ $1.89
  • Resistance Level
  • ZBAI N/A
  • MYNZ $2.25
  • Average True Range (ATR)
  • ZBAI 0.00
  • MYNZ 0.22
  • MACD
  • ZBAI 0.00
  • MYNZ 0.04
  • Stochastic Oscillator
  • ZBAI 0.00
  • MYNZ 62.68

About ZBAI ATIF Holdings Limited Ordinary Shares

ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.

About MYNZ Mainz Biomed N.V.

Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.

Share on Social Networks: